Analyst Research Report Snapshot

Title:

GW PHARMACEUTICALS - POT LUCK

Price:

$10.00

Provider:

Edison Investment Research

Date:

28 Sep 2009

Pages:

12

Type:

AcrobatPDF

Companies referenced:

GWP.L

Available for Immediate Download
Summary:

GW Pharmaceuticals offers an investment geared to the near-term success of Sativex, a therapeutic extract of the cannabis plant. Sativex is on the brink of receiving EU regulatory approval, triggering milestone revenue and its first meaningful sales. GW’s expertise in plant genetics and ability to operate under UK Home Office licence could make it the first company legally to derive a significant financial benefit from the cannabis plant. FOR MORE INFORMATION ON THE ATTACHED RESEARCH PLEASE CALL 020 3077 5700, EMAIL RESEARCH@EDISONINVESTMENTRESEARCH.CO.UK OR VISIT WWW.EDISONINVESTMENTRESEARCH.CO.UK

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.